{"id":"W3030178583","doi":"10.1200/jco.20.00793","title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":759,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Lung cancer; Hazard ratio; Clinical endpoint; Etoposide; Population; Gastroenterology; Progression-free survival; Oncology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Chemotherapy; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002590653,0.001884739,0.003184295,0.0005189857,0.000498857,0.001068785,0.001090698,0.002106276,0.008136226],"category_scores_gemma":[0.001897,0.0009440356,0.001631002,0.0004410607,0.001074486,0.001027729,0.0004030068,0.002765093,0.001610383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005855642,"about_ca_system_score_gemma":0.001375284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006640314,"about_ca_topic_score_gemma":0.001516396,"domain_scores_codex":[0.9991753,0.0004355999,0.00006125977,0.0001616972,0.00007927103,0.00008682374],"domain_scores_gemma":[0.9991555,0.0002172612,0.0001977515,0.00006879679,0.00007160048,0.0002891411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9704198,0.01177346,0.0002722448,0.0009005896,0.000768532,0.00002384688,0.00002826345,0.0001756766,0.0037964,0.00008773233,0.0007684411,0.01098506],"study_design_scores_gemma":[0.9525111,0.04537589,0.0006129572,0.00002855857,0.0003619631,0.00001778163,0.0000066276,0.0001689999,0.0003665404,0.00006642157,0.0004759065,0.000007228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9525437,0.01230047,0.002459685,0.001320579,0.001497475,0.02137579,0.003555694,0.00041294,0.004533598],"genre_scores_gemma":[0.9628766,0.007339079,0.002969863,0.002174896,0.0008819253,0.01606189,0.001713185,0.00005179899,0.005930777],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008136226,"threshold_uncertainty_score":0.02721834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2457992469628378,"score_gpt":0.5415262119285564,"score_spread":0.2957269649657187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}